Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 119, Issue 6, 2011, Pages 362-365

  Kanazawa, I ^a   Yamamoto, M ^a   Yamaguchi, T ^a   Sugimoto, T ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

advanced glycation end product; metformin; pentosidine; pioglitazone; type 2 diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HEMOGLOBIN A1C; INSULIN; METFORMIN; PENTOSIDINE; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET THERAPY; DRUG EFFECT; FEMALE; HUMAN; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ARGININE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LYSINE; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 79958295233     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1267953     Document Type: Article

References (31)

1. Aso Y, Inukai T, Tayama K et al,. Serum concentrations of advanced glycation end products are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol 2000 37 87-92 (Pubitemid 32009315)
2. Beisswenger P, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab 2003 29 6S95-6S103 (Pubitemid 37187096)
3. Betteridge DJ. What is oxidative stress? Metabolism 2002 49 3-8
4. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988 318 1315-1321
5. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995 46 223-234
6. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 813-820 (Pubitemid 34000785)
7. Daimon M, Ono Y, Saito T et al,. Increased serum levels of pentosidine, but not carboxymethyl lysine, in type 2 diabetes without obvious diabetic nephropathy. Diabetes Care 1999 22 877-878 (Pubitemid 29220813)
8. Goldin A, Beckman JA, Schmidt AM et al,. Advanced glycation end products sparking the development of diabetic vascular injury. Circulation 2006 114 597-605 (Pubitemid 44199649)
9. Grandhee SK, Monnier VM. Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. J Biol Chem 1991 266 11649-11653 (Pubitemid 21906998)
10. Hannon R, Blumsohn A, Naylor K et al,. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998 13 1124-1133 (Pubitemid 28311780)
11. Iida KT, Kawakami Y, Suzuki M et al,. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am J Physiol Endocrinol Metab 2003 284 E1125-E1130 (Pubitemid 36617458)
12. Kilhovd BK, Berg TJ, Birkeland KI et al,. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999 22 1543-1548 (Pubitemid 29418253)
13. Lapolla A, Reitano R, Baccarin L et al,. Pentosidine plasma levels and relation with metabolic control in diabetic patients. Horm Metab Res 2005 37 252-256 (Pubitemid 40756348)
14. Meil M, Perier C, Ferron C et al,. Serum pentosidine as an indicator of Alzheimer's disease. J Alzheimers Dis 2002 4 93-96 (Pubitemid 34578704)
15. Miyata T, Ishikawa S, Asahi K et al,. 2-Isopropylidenehydrozono-4-oxo- thiazolidin-5-ylacetanilide (OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotid artery: role of glycoxidation and lipoxidation reactions in vascular tissue damage. FEBS Lett 1999 445 202-206 (Pubitemid 29101561)
16. Monnier VM, Sell DR, Nagaraj RH et al,. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. Diabetes 1992 41 36-41
17. 1c as markers of diabetic complications. Diabetes 1999 48 870-880 (Pubitemid 29153089)
18. Odetti P, Fogarty J, Sell DR et al,. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992 41 153-159
19. Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 1993 212 101-105 (Pubitemid 23064605)
20. Rahbar S, Natarajan R, Yerneni K et al,. Evidence that pioglitazone, metformin and pentoxifylline are inhibitiors of glycation. Clin Chim Acta 2000 301 65-77
21. Sanaka T, Funaki T, Tanaka T et al,. Plasma pentosidine levels measured by a newly developed method using ELISA in patients with chronic renal failure. Nephron 2002 91 64-73 (Pubitemid 34522834)
22. Schwartz AV, Garnero P, Hillier TA et al,. Health, Aging, and Body Composition Study. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab 2009 94 2380-2386
23. Singh R, Barden A, Mori T et al,. Advanced glycation end-products a review. Diabetologia 2001 44 129-146
24. Sugiyama S, Miyata T, Ueda Y et al,. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol 1998 9 1681-1688
25. Tessier D, Maheux P, Khalil A et al,. Effect of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism 1999 48 897-903 (Pubitemid 29310047)
26. Torrens JI, Skurnick J, Davidow AL et al,. Study of Women's Health Across the Nation (SWAN) Ethnic differences in insulin sensitivity and beta-cell function in premenopaulsa or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN). Diabetes Care 2004 27 354-361 (Pubitemid 38174057)
27. van Deemter M, Ponsioen TL, Bank RA et al,. Pentosidine accumulates in the aging vitreous body: a gender effect. Exp Eye Res 2009 88 1043-1050
28. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001 17 436-443 (Pubitemid 34030746)
29. Weiss MF, Rodby RA, Justice AC et al,. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group. Kidney Int 1998 54 193-202 (Pubitemid 28288035)
30. Yamamoto M, Yamaguchi T, Yamauchi M et al,. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008 93 1013-1019 (Pubitemid 351398587)
31. Yoshida N, Okumura K, Aso Y. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes. Metabolism 2005 54 345-350 (Pubitemid 40250094)